

SUVEN Life Sciences

Communication to investors June 2018

14-Aug-18

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW Quarter 1 – June 2018




	Q1-FY19 to Q4-FY18	Q1-FY19 to Q1-FY18
Growth in Revenue	-10.39%	36.24%
Growth in PAT	-37.77%	31.23%
Growth in EBIDTA	-33.95%	30.35%
Growth Pre-R&D EBIDTA	-29.85%	23.05%
Increase in R&D costs	-5.48%	-0.14%

MAJOR PROFITABILITY RATIOS

	30 Jun 2018	31 Mar 2018	30 Jun 2017
PAT to Income	19.41%	27.95%	20.15%
EBIDTA to Income	33.21%	45.06%	34.72%
Cash Flow to Income	22.16%	30.35%	23.69%
Pre-R&D EBITDA to Income	41.22%	52.65%	45.64%
R&D to Income	8.00%	7.59%	10.92%



INCOME COMPARISON




14-Aug-18



PROFIT COMPARISON

PAT Comparison



14-Aug-18



EBIDTA COMPARISON

EBIDTA Comparison




14-Aug-18



R & D – EXPENDITURE

R&D Expenditure



14-Aug-18



PRE-R&D EBIDTA

Pre R&D EBIDTA




2018-19 Q1 results

14-Aug-18



PRE-R&D CASHFLOW

Pre R&D Cash Flow





Financial Snapshot All figures are in INR Million, other than ratios and EPS

	Q1 FY19	Q4 FY18	QoQ growth	Q1 FY18	YoY growth
Income	1,997.90	2,229.49	-10.39%	1,466.42	36.24%
Pre-R&D EBITDA	823.47	1,173.83	-29.85%	669.22	23.05%
Pre-R&D EBITDA Margin	41.22%	52.65%		45.64%	
EBITDA	663.59	1,004.68	-33.95%	509.10	30.35%
EBITDA Margin	33.21%	45.06%		34.72%	
EBIT	607.81	949.03	-35.95%	456.94	33.02%
EBIT Margin	30.42%	42.57%		31.16%	
Financing costs	10.68	12.54		12.70	
Taxes	209.41	313.42		148.77	
Taxes to Profit	35.07%	33.47%		33.49%	
Net Profit after tax	387.73	623.07	-37.77%	295.46	31.23%
NP Margin	1 9.4 1%	27.95%		20.15%	-
EPS (basic & diluted not annualized)	3.05	4.90	<u> </u>	2.32	
Paid up share capital One Rupee					
Share)	127.28	127.28	-	127.28	-
Depreciation	55.08	53.61	-	51.92	-
R&D expenses	159.89	169.15	-5.48%	160.12	-0.14%

News Updates



- SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's initiated in USA, so far enrolled 494 patients against target of 537 patients in the study.
- During the period Suven secures 15 product patents covering countries - Australia, China, India, Israel, Mexico, New Zealand, Norway, Singapore, South Korea and USA
- Suven Life Sciences participated in Sleep 2018 conference held in Baltimore in June 2018
- Suven Life Sciences participated and presented in Jefferies Global Healthcare Conference held in New York in June 2018
- Suven Life Sciences exhibited and presented in AAIC 2018, held in Chicago in July 2018